Minakem Generic APIs Minakem Generic APIs

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Salubris Biotherapeutics","sponsor":"SHENZHEN SALUBRIS PHARMACEUTICALS CO.LTD.","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"Salubris Biotherapeutics Announces $35 Million Financing to Advance Development Activities and Provides Pipeline Updates","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Salubris Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"Salubris Biotherapeutics Announces $35 Million in Financing and Provides Pipeline Progress Update","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by Salubris Biotherapeutics

    Menu

    Salubris Biotherapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Salubris Biotherapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Salubris Biotherapeutics Announces $35 Million in Financing and Provides Pipeline Progress Update

              Details:

              JK07 is a recombinant fusion protein consisting of a fully human immunoglobulin IgG1 monoclonal antibody, which is being evaluating in the mid-stage clinical trials for the treatment of patients with HFrEF and HFpEF.

              Lead Product(s): JK07

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: JK07

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Undisclosed

              Deal Size: $35.0 million Upfront Cash: Undisclosed

              Deal Type: Financing April 22, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Salubris Biotherapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Salubris Biotherapeutics Announces $35 Million Financing to Advance Development Activities and Provides Pipeline Updates

              Details:

              The financing will be used to advance and accelerate JK07, including the planned initiation of the first Phase 2 study in HFrEF and the continuation of the ongoing Phase 1b clinical trial in heart failure with preserved ejection fraction.

              Lead Product(s): JK07

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: JK07

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: SHENZHEN SALUBRIS PHARMACEUTICALS CO.LTD.

              Deal Size: $35.0 million Upfront Cash: Undisclosed

              Deal Type: Financing March 28, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Symbiotec: Global API manufacturer, specializing in Cortico-Steroids & Steroid-Hormone APIs.
              Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
              Post Enquiry
              POST ENQUIRY